Herring roe PLs promote SPM biosynthesis in macrophages and a keratinocyte/fibroblast co-culture as model of psoriasis

This study demonstrates that herring roe phospholipids promote the biosynthesis of specialized pro-resolving mediators (SPMs) in macrophages and psoriasis-relevant skin cell co-cultures, suggesting a mechanism by which these lipids facilitate the resolution of inflammation in psoriasis.

The Gist

The Big Picture: Turning Off the "Fire" in Psoriasis

Imagine your body is a house. When you get a cut or an infection, the body sends in the "firefighters" (immune cells) to put out the fire (inflammation). Usually, once the fire is out, the firefighters pack up and go home. This is called resolution.

But in people with psoriasis, the fire alarm is stuck in the "ON" position. The firefighters never leave; they keep running around, causing smoke, heat, and damage to the house (the skin). This leads to red, scaly, itchy patches.

This paper investigates a special ingredient found in herring roe (fish eggs) that might help the body finally turn off that stuck alarm and tell the firefighters to go home.

---

The Secret Weapon: "Specialized Pro-Resolving Mediators" (SPMs)

For a long time, scientists thought the fire just slowly died out because the fuel ran out. But recently, we learned that the body actually has a specific "off switch" made of tiny chemical messengers called SPMs.

Think of SPMs as the supervisors who tell the firefighters: "Great job, the fire is out. Now, please stop fighting, clean up the mess, and help rebuild the house."

The problem is that in diseases like psoriasis, the body either doesn't make enough of these supervisors, or the "fire" is so loud that the supervisors can't be heard.

The Experiment: Testing the Herring Roe Oil

The researchers wanted to see if Herring Roe Oil (HRO) could help the body make more of these "supervisors" (SPMs). They used two different "test kitchens" to see how the oil worked:

1. The Macrophages (The Clean-Up Crew): They took immune cells from human blood (macrophages) and treated them with the oil. These cells are like the general managers of inflammation.
2. The Skin Model (The House): They grew a mix of skin cells (keratinocytes and fibroblasts) that were acting like psoriatic skin (angry and inflamed) and treated them with the oil.

They compared the whole oil (HRO) against a super-concentrated version of just the phospholipids from the oil (PEHeRo). Think of HRO as a whole fruit smoothie, and PEHeRo as the pure, concentrated juice extracted from that fruit.

What They Found: The "Off Switch" Was Flipped!

The results were exciting. When they added the herring roe oil to the cells, something magical happened:

• The Production Line Sped Up: The cells didn't just sit there; they started manufacturing massive amounts of the "supervisors" (SPMs).
• The Star Players: The oil specifically boosted the production of two very important supervisors: RvE2 and RvE3.
  • Analogy: If inflammation is a chaotic riot, RvE3 is the police chief who specifically tells the rioters to stop fighting and go home. This is huge because RvE3 is known to calm down the specific pathway (IL-23/IL-17) that causes psoriasis.
• The Clean-Up Crew Changed: The immune cells treated with the oil started acting more like "peacekeepers" (reparative phenotype) rather than "warriors." They started cleaning up the damage and preparing the skin to heal.
• The Skin Model Responded: Even in the angry skin cells, the oil helped turn on the production of these healing chemicals, suggesting it could work directly on the skin, not just the immune system.

The "Fish Egg" Advantage: Why Herring Roe?

You might wonder, "Why herring roe? Why not just take fish oil pills?"

The paper suggests that the form of the oil matters. Herring roe oil is rich in phospholipids (a type of fat that makes up cell membranes).

• Analogy: Imagine you are trying to deliver a package (the healing fat) to a house.
  • Standard fish oil is like a package wrapped in heavy, hard cardboard (triglycerides). It takes a lot of effort for the body to unwrap it.
  • Herring roe oil is like a package wrapped in a soft, dissolvable envelope (phospholipids). The body can open it easily and get the good stuff inside much faster.

The researchers found that the concentrated phospholipid version (PEHeRo) was actually better at triggering the production of healing chemicals than the whole oil, even though it had fewer raw ingredients. This proves that the "packaging" (the phospholipids) helps the body do its job more efficiently.

The Conclusion: A New Way to Heal

This study shows that herring roe oil isn't just a generic anti-inflammatory. It acts like a chemical key that unlocks the body's own ability to stop inflammation and start healing.

Instead of just trying to "block" the fire (which is what many current psoriasis drugs do), this oil helps the body finish the job and return to normal. It tells the immune system, "The fire is out, let's go home and fix the house."

In short: Herring roe oil helps the body make its own "healing supervisors," which could be a powerful new way to treat psoriasis and other chronic inflammatory diseases by helping the body naturally resolve inflammation rather than just suppressing it.

Technical Summary

1. Problem Statement

Psoriasis is a chronic immune-mediated inflammatory disease (IMID) characterized by local and systemic inflammation, driven by dysregulated cytokine pathways (specifically the IL-23/IL-17 axis) and a failure in the active resolution of inflammation. While the role of pro-inflammatory eicosanoids is well-established, the active processes of inflammation resolution mediated by Specialized Pro-resolving Mediators (SPMs) are often impaired in chronic diseases.

Marine oils, particularly those rich in phospholipids (PLs) like Herring Roe Oil (HRO), have shown clinical efficacy in reducing psoriasis symptoms (PASI scores) and modulating immune responses. However, the specific molecular mechanisms by which HRO and its purified phospholipid fraction (PEHeRo) promote inflammation resolution via endogenous SPM biosynthesis in human immune and skin cells remain poorly understood. This study aims to elucidate whether HRO/PEHeRo treatment stimulates the de novo biosynthesis of SPMs in macrophages and a psoriasis-mimicking skin co-culture.

2. Methodology

The study employed a multi-faceted in vitro approach combining lipidomics, cell biology, and molecular genetics:

• Lipid Characterization:
  • Materials: Immature herring roe (IHR) was processed into HRO (standardized oil) and PEHeRo (>90% phospholipids).
  • Analysis: Fatty acid profiles were determined via GC-FID. Lipid mediator content (SPMs and precursors) in the oils was quantified using LC-MS/MS with deuterated internal standards.
• Cell Models:
  • Macrophages: Primary human monocyte-derived macrophages (MDMs) were differentiated from peripheral blood mononuclear cells (PBMCs) using M-CSF.
    • Stimulation: Cells were either pre-treated with HRO/PEHeRo followed by LPS + IFN-γ, or co-stimulated with LPS (1 ng/mL) and the lipids.
  • Skin Co-culture: A model mimicking psoriasis was established using HaCaT keratinocytes and primary human dermal fibroblasts, stimulated with IL-17A (100 ng/mL) to induce an inflammatory state.
• Lipid Mediator Quantification:
  • Cell supernatants were analyzed using a validated LC-MS/MS protocol (multiple reaction monitoring) to quantify SPMs (Resolvins, Protectins, Maresins, PCTRs) and their precursors (hydroxy-fatty acids) across four metabolomes: DHA, n-3 DPA, EPA, and Arachidonic Acid (AA).
• Gene Expression:
  • RT-qPCR was used to assess the expression of key biosynthetic enzymes (COX2, ALOX5, ALOX12, ALOX15, ALOX15B) in both cell types.
• Statistical Analysis:
  • Data were analyzed using ANOVA, Mann-Whitney U tests, and Partial Least Squares Discriminant Analysis (PLS-DA) to identify drivers of metabolic shifts.

3. Key Contributions

• Mechanistic Insight: The study provides the first evidence that HRO and its phospholipid fraction (PEHeRo) actively stimulate the de novo biosynthesis of SPMs in human macrophages and psoriasis-mimicking skin cells, rather than merely delivering exogenous mediators.
• Phospholipid Superiority: It demonstrates that the purified phospholipid fraction (PEHeRo) is more potent than the whole oil (HRO) in driving DHA-derived SPM biosynthesis, suggesting that the lipid matrix (phospholipids vs. triacylglycerols) influences bioavailability and enzymatic conversion efficiency.
• Skin Cell Metabolism: It establishes that keratinocytes and fibroblasts possess the enzymatic machinery to synthesize SPMs and that this capacity is upregulated by marine lipid supplementation even in an IL-17A-driven inflammatory environment.
• Pathway Specificity: The research identifies specific enzymatic pathways (e.g., ALOX15B for EPA-derived RvE3) that are preferentially activated in these cell systems.

4. Key Results

A. Oil Composition

• HRO and PEHeRo are rich in DHA and EPA (3:1 ratio) and contain pre-existing SPMs (RvD5, RvD6, PDX, MaR1/2).
• HRO contained >10-fold higher levels of pre-formed lipid mediators than PEHeRo, yet PEHeRo induced stronger SPM biosynthesis in cells, ruling out exogenous mediator delivery as the primary mechanism.

B. Macrophage Response (MDMs)

• SPM Upregulation: Treatment with HRO and PEHeRo significantly upregulated the biosynthesis of SPMs from DHA, EPA, and n-3 DPA metabolomes.
• Dominant Mediators:
  • RvE3 (EPA-derived) was the most abundant SPM across all conditions.
  • RvD2 and PDX (DHA-derived) were consistently upregulated.
  • PCTR2 (Protectin Conjugate in Tissue Regeneration) was detected, indicating a shift toward a reparative macrophage phenotype.
• Enzyme Expression: Key enzymes (COX2, ALOX5, ALOX12, ALOX15B) were expressed. HRO treatment appeared to attenuate COX2 gene expression.
• PLS-DA Analysis: Confirmed distinct metabolic profiles between treated and untreated groups. PEHeRo induced a distinct cluster separation compared to HRO, driven largely by DHA-derived SPMs (RvD1, RvD4, PD1, PDX).

C. Skin Co-culture Response (Keratinocytes/Fibroblasts)

• SPM Biosynthesis: Despite using a 100-fold lower concentration of HRO compared to macrophage experiments, significant upregulation of DHA and EPA-derived SPMs was observed.
• Pathway Preference:
  • DHA/DPA: Biosynthesis favored the 17-hydroxy pathway (17-HDHA, 17-HDPA), mediated by ALOX15, leading to Resolvins D series. 14-hydroxy pathways (Maresins) were minimal.
  • EPA: Biosynthesis favored the 18-hydroxy pathway (18-HEPE), leading to RvE3 and RvE2.
• IL-17A Impact: IL-17A stimulation generally reduced EPA-derived SPMs (specifically RvE3) but did not abolish the ability of HRO to promote biosynthesis.
• Gene Expression: The full enzymatic machinery (COX2, ALOX12, ALOX15, ALOX15B) was present in skin cells, confirming their capacity for endogenous synthesis.

5. Significance

• Therapeutic Mechanism for Psoriasis: The study identifies a plausible mechanism for the clinical efficacy of HRO in psoriasis: the promotion of endogenous SPM biosynthesis (specifically RvE3, RvD2, and PDX) which actively resolves inflammation and promotes tissue repair in the skin niche.
• Role of RvE3: The consistent upregulation of RvE3 is particularly significant, as it is known to attenuate inflammation via the IL-23/IL-17A axis, a central driver of psoriatic pathology.
• Phospholipid Bioavailability: The findings support the hypothesis that marine phospholipids (PEHeRo) offer superior bioavailability and metabolic conversion efficiency compared to standard triacylglycerol-based fish oils or crude extracts.
• Reparative Phenotype: The detection of PCTR2 suggests that HRO treatment not only resolves inflammation but also actively promotes tissue regeneration, a critical factor in chronic skin diseases.
• Future Directions: These in vitro findings provide a strong rationale for further in vivo clinical trials to confirm that oral HRO/PEHeRo supplementation can modulate the lipid mediator landscape in psoriasis patients to drive disease resolution.